Benitec Biopharma Inc BNTC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
-
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
-
Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar
-
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study
Trading Information
- Previous Close Price
- $9.81
- Day Range
- $8.49–10.26
- 52-Week Range
- $2.69–12.89
- Bid/Ask
- $9.07 / $9.47
- Market Cap
- $95.62 Mil
- Volume/Avg
- 51,561 / 26,669
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
- Website
- https://www.benitec.com
Comparables
Valuation
|
Metric
|
BNTC
|
TSHA
|
UTHR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 51.55 | 15.15 |
Price/Book Value | 2.02 | 3.72 | 2.78 |
Price/Sales | — | 31.27 | 6.69 |
Price/Cash Flow | — | — | 14.35 |
Price/Earnings
BNTC
TSHA
UTHR
Financial Strength
|
Metric
|
BNTC
|
TSHA
|
UTHR
|
|---|---|---|---|
Quick Ratio | 10.38 | 5.05 | 3.92 |
Current Ratio | 10.49 | 5.22 | 4.35 |
Interest Coverage | — | −52.79 | 22.67 |
Quick Ratio
BNTC
TSHA
UTHR
Profitability
|
Metric
|
BNTC
|
TSHA
|
UTHR
|
|---|---|---|---|
Return on Assets (Normalized) | −87.11% | −40.83% | 16.95% |
Return on Equity (Normalized) | −108.14% | −216.63% | 20.53% |
Return on Invested Capital (Normalized) | −110.40% | −77.31% | 16.62% |
Return on Assets
BNTC
TSHA
UTHR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xgdznjrkgf | Hcb | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Lpjgdfmz | Lqdmbh | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vsrgnyvdx | Zhdczk | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pvrwkcld | Fqgjpb | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Pqrsgrm | Xlzsg | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Qstwqldz | Yrss | $29.2 Bil | |||
| Moderna Inc
MRNA
| Qczhywssg | Jjpz | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Ntcqhlhjq | Yxhv | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hjqvfdk | Ghfxph | $13.2 Bil | |||
| Incyte Corp
INCY
| Pdpkjlz | Twxgh | $13.0 Bil |
United States